TrialInvestigational new drugs2022

A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors.

Nabil Adra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.